(TXMD) – FDA Approves TherapeuticsMD’s Low Dose Bijuva

TherapeuticsMD Inc (NASDAQ: TXMD) is trading sharply higher after it announced that the FDA approved a low dose version of Bijuva, an oral hormone therapy to treat women with vasomotor symptoms due to menopause.